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ABSTRACT 
 
Infectious diseases remain a serious public health challenge worldwide 
and are the leading cause of death in many developing countries. The rapid 
detection of pathogens is vital for the control and prevention of the infectious 
diseases. New tools are needed to enable rapid detection, identification, and 
reporting of infectious viral and microbial pathogens in a wide variety of point-of-
care applications that impact human and animal health. With the rapid 
development of mobile technologies, mobile devices have provided a novel and 
effective approach to identify and report infectious diseases.  
In this work, two types of smartphone-based detection platforms are 
developed for mobile infectious disease detection. The first one is for the 
detection of human immunodeficiency virus. The second one is for the 
multiplexed detection of nucleic acids of pathogens for equine respiratory 
infections. Both platforms utilize a smartphone camera as the sensor in 
conjunction with a handheld cradle that interfaces the phone with a microchip for 
the on-chip nucleic acid testing of infectious diseases.   
This work provides a mobile, simple and inexpensive capability for 
clinicians to perform infectious disease diagnostics, and it represents a significant 
stride towards a practical solution to the infectious disease diagnostics at 
resource-limited settings. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Infectious disease 
Historically, infectious diseases have hugely impacted humankind as one 
of the most important contributors to human morbidity and mortality [1]. Today, 
such diseases remain a serious public health threat. Despite the significant 
accomplishments made in the diagnosis, prevention and treatment of infectious 
diseases during the 20th century [2], the outbreaks of new infectious diseases such 
as HIV/AIDS, severe acute respiratory syndrome (SARS), Ebola virus disease 
(EVD), and Zika virus disease have significantly increased during the past two 
decades [3]. The re-emergence of diseases previously regarded as under control 
such as malaria and cholera has also drawn considerable attention [4]. According 
to the world health report released by the World Health Organization (WHO) in 
2004, infectious diseases are responsible for approximately 25.9% of global 
deaths, with the leading causes being lower-respiratory infections (6.9%), 
HIV/AIDS (4.9%), diarrhea (3.2%) and tuberculosis (TB) (2.7%) [5]. While 
infectious diseases are not prevalent in the developed countries, large parts of 
developing countries, especially sub-Saharan African countries, are still 
vulnerable to such diseases due to the insufficient medical resources and effective 
public health surveillance system, and therefore account for more than half of 
infectious disease deaths [6]. On the other hand, with the rapid population 
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mobility brought by globalization, the differences in infectious disease 
epidemiology are reduced among different regions of the world [7]. Local 
epidemics can quickly become regional or even global issues.  
Infectious diseases can also destructively affect animals and plants. The 
incidence of infectious diseases among animals and plants can pose a serious 
threat to food safety, environment protection and national economies. For 
example, the outbreaks of Avian influenza between 1996 and 2008, which is 
commonly known as the “bird flu” because of the viruses adapted to birds, spread 
widely among Asian and European countries and caused an economic loss tens of 
billions of dollars [8]. The various subtypes of avian influenza viruses directly led 
to the deaths of tens of millions of birds. In addition, to control the spreading of 
the influenza, hundreds of birds had to be slaughtered and disposed of. Poultry 
contributes to approximately 20% of the protein consumption in developing 
countries [9]. Such outbreaks greatly impacted on the poultry industry of the 
affected countries in terms of decrease in export and loss of consumer confidence, 
as infectious disease is listed as one of the few reasons authorized by World Trade 
Organization (WTO) for blocking imports of agricultural products.   
Infectious diseases are caused by pathogens. The types of pathogens cover 
a broad spectrum of basic organisms in microbiology, including virus, bacterium, 
fungus and parasite. These pathogens work as the agents for infectious diseases 
when they spread from an infected host individual or group to another susceptible 
host. The transmission of pathogens can occur through many different routes, 
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including direct or indirect contact, airborne, blood, or other body fluids. In recent 
years, increasing human activities such as migration and urbanization have 
created many new pathways for transmission of pathogens, making the 
transmission even easier than before [10]. Other factors that facilitate the 
pathogen transmission include climate change, biodiversity change and nutrient 
pollution [11]. 
It is worth noting that co-infections by more than one pathogen strain have 
become commonplace and can carry greater risk than a single infection. Co-
infections have been a contributing factor to the mortality of infectious diseases in 
developing countries as many assays only test for one agent and miss the presence 
of a co-infection. One typical example is the co-infection between human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV). An estimated 2.3 
million people living with HIV are co-infected with hepatitis C virus (HCV) 
globally [12]. Viral hepatitis usually progresses faster and causes more liver-
related health problems among people with HIV than among those who do not 
have HIV [13]. Co-infection can also occur when one pathogen has multiple 
strains or genotypes. Strains are important because they can differ greatly in many 
traits, including growth rate, virulence, infectivity, antigenicity and drug 
resistance [14]. The study of multiple-strain infections can improve the 
understanding of host-pathogen interactions, disease dynamics, and novel control 
approaches. And the capability of simultaneously detecting multiple pathogen 
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strains is highly desirable for a variety of medical researches and clinical 
applications. 
To identify the presence or absence of certain pathogens is the key step for 
the diagnosis of infectious diseases. Conventional diagnostic approaches often 
rely on the use of microbial culture and microscopic examination to measure the 
existence of specific micro-organisms [15]. But culture methods often have low 
yield and microscopy is relatively insensitive. Such detection requires substantial 
time, equipment and training, and not all pathogens can be cultured and clearly 
distinguished from others under microscope. Many other diagnostic approaches 
involve the use of biochemical tests to indirectly identify the pathogens through 
measuring enzymes or antibodies that are correlated to particular types of micro-
organisms [16]. Emerging novel approaches such as nucleic acid testing and next-
generation sequencing are also applied for the rapid and accurate diagnostics of 
infectious diseases [15]. Generally speaking, the diagnostic methods must be 
accurate, simple and affordable for the population for which they are intended. 
Furthermore, considering the communicable nature of the infectious disease and 
the potential risks brought by the delay of effective treatment, they must provide 
results in time to allow for the establishment of the following control measures 
and treatment [17]. For some disease outbreaks, early diagnosis can play a critical 
role in interrupting the transmission of the pathogens. The ability of rapid 
detection and timely reporting can greatly improve the current way that the 
infectious diseases are managed.  
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1.2 Nucleic acid test 
In recent years, the development of molecular diagnostic techniques has 
brought significant improvements in the diagnosis and monitoring of infectious 
diseases [18]. The nucleic acid test (NAT), also referred to as nucleic acid 
amplification test (NAAT), is a molecular technique that has been widely used for 
the detection of various infectious agents [19]. The NAT diagnosis is able to 
identify the pathogens through the detecting and amplification of their genomic 
sequences, known as the target DNA or RNA sequence. The amplification 
process of the target sequence can generate thousands to millions of copies of the 
target genomic fragment, making a large amount of nucleic acids. The detection 
results can be indicated by measuring the fluorescent labels that are designed to 
bind to the nucleic acids. Compared to traditional diagnostic methods, the NAT 
technologies offer several advantages. Firstly, NAT is a highly sensitive method 
since it can detect low levels of DNA or viral RNA. Secondly, the detection is 
specific since only the target sequences can be amplified. Thirdly, the diagnosis 
process can be rapid, making it possible to have early treatment of the diseases. 
Lastly, the NAT diagnostic has the potential of multiplexing detection, the ability 
to detect multiple pathogens in a single clinical specimen. Currently, there are two 
major types of NAT approaches: one involves a periodic thermal cycling process 
and the other involves an isothermal process.  
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Polymerase chain reaction (PCR) is an in vitro enzymatic reaction that can 
provide large quantities of a specific DNA fragment with the help of repeated 
thermal cycles under the deriving of DNA polymerase [20]. This easy-to-carry out 
technique has become a very popular and often indispensable tool in medical and 
biological laboratories for numerous types of applications, including DNA 
cloning, DNA sequencing, gene function analysis and the diagnosis of infectious 
disease. The thermal cycles, comprised of alternating heating and cooling of the 
reaction, can help the separation and enzymatic replication of the target DNA. 
During the thermal cycles, the primers, which are short DNA fragments 
containing the complementary genomic sequence of the target DNA, work with 
DNA polymerase to generate replicas of the target, in the format of a chain 
reaction. The process of a classical PCR is illustrated in Figure 1.1. For each PCR 
cycle, a double stranded DNA (dsDNA) is firstly denatured at a high temperature 
(~ 95°C) , which can break all the hydrogen bonds between the two strands of the 
DNA, and create two complementary single strand DNNAs (ssDNA). Secondly, 
the ssDNAs are annealing at low temperature (~ 55°C) to allow for the binding of 
the specifically designed primers at the ends of the ssDNA sequence of interest.  
Finally, the DNA polymerase binds to the primer sites and catalytically elongates 
the primer to synthesize a new DNA strand complementary to the DNA template 
at ~ 72°C. Ideally, the number of target DNA copies doubles after each cycle, and 
the newly synthesized DNAs become the sequence template for the next cycle. 
Through this kind of chain reaction, the number of target DNA copies can be 
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exponentially amplified. PCR is traditionally performed in a small reaction tube in 
a thermal cycler, and the amplified DNAs can be visualized through gel 
electrophoresis or fluorescent labels [21].   
Loop mediated isothermal amplification (LAMP) is a nucleic acid 
amplification technique that was first reported in 2000 [22].  Compared to PCR, 
the major feature of LAMP is that it does not need the series of temperature 
changes, and it can be carried out at a constant temperature. At the LAMP 
reaction temperature (~60-65°C), the double-stranded DNA is in a “dynamic 
equilibrium,” and the polymerase is prone to both strand displacement activity 
and replication activity. The detail of the LAMP process is illustrated in Figure 
1.2 [23]. Typically, 4 different primers are used in LAMP, which increases the 
specificity of the LAMP detection, as shown in Figure 1.2a. With the help of the 
polymerase, the primers anneal to 6 different regions on the target DNA and make 
the initial elongations (Figure 1.2b). The output of the first stage annealing, 
elongation and displacement is a dumbbell-like structure with stem-loops at both 
ends, which also serves as the template for the following cycling amplification 
steps (Figure 1.2c). In each cycle, one strand is displaced during the elongation 
with the addition of new loops. The released single strand can form a new stem-
loop structure that is complementary to the initial template, and then it uses itself 
as the template to start the new synthesis. The reaction will stop when the 
concentrations of the reagents and enzymes become low or the buffer capacity is 
reached. 
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Both PCR and LAMP can be used for the detection of RNA targets 
through the reverse transcription (RT) process, which can create complementary 
DNA from an RNA template [24].  
 
1.3 Microfluidic devices 
The microfluidic technologies have been under rapid development in 
recent years, and they have become powerful tools in a wide range of biomedical 
research and applications [25]. Many of the complex laboratory assays performed 
with expensive and bulky instruments can be miniaturized and performed on an 
integrated microfluidic system, which is also often called a lab-on-chip (LOC) 
[26]. Such LOC systems typically consume only small volumes of analytes, 
provide high sensitivity detection, and can be fabricated from low-cost materials, 
making it possible to achieve point-of-care (POC) diagnostics, which is defined as 
analytical testing performed outside the central laboratory using devices that can 
be easily transported to the vicinity of the patient [27]. The POC feature provided 
by microfluidic devices is of great importance in resource-limited settings such as 
developing countries. The miniaturization of laboratory instruments and the 
simplification of the sample preparation process can allow the development of 
high-throughput, easy-to-operate, portable and affordable assays that can be 
accessible to a large group of people, and that are critical to global health 
applications.  
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There are currently two major types of microfluidic devices: one type is 
continuous-flow microfluidics and the other type is droplet-based microfluidics 
[28]. Continuous-flow is the mainstream operation approach for microfluidic 
devices because of the easy implementation and the good control of the fluids. 
The continuous liquid streams in the microfluidic channels are usually driven by 
external pressure, mechanical pumps, capillary force or electrokinetic mechanism. 
The droplet-based microfluidics, on the other hand, involve the generation and 
manipulation of discrete volumes of fluids inside the microfluidic channels. 
Compared to the continuous-flow microfluidic devices, the droplet-based 
microfluidic devices are able to manipulate the motion of single dispersed 
droplets, so as to achieve better control of the fluid volume and perform high 
throughput analyses. The droplets can be generated by several different methods, 
for example by utilizing the geometry of microfluidic channels and the electrical 
properties of the fluids [29]. 
Microfluidic systems are usually fabricated from silicon, glass, quartz, and 
various polymeric materials [30]. The fabrication approaches for the microfluidic 
devices have been extensively studied with the help of the well-established 
semiconductor fabrication technologies, especially the micro-electro-mechanical-
systems (MEMS) technologies [31, 32]. The selection of materials is usually 
dependent on the specific application of the microfluidic device. Many 
microfluidic devices are made of polymers such as PDMS (Polydimethylsiloxane) 
and PMMA (polymethyl methacrylate) because of their good biocompatibility, 
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low cost and simple fabrication process. PDMS is an optically transparent, soft 
elastomer that can be easily engineered into various shapes using thermal curing 
process. But the use of polymer materials is problematic for some fluorescence-
based detection due to the strong auto-fluorescence [33]. Glass is another 
commonly used transparent material but with low auto-fluorescence. Silicon is an 
opaque material, and has the unique advantage of high thermal conductivity. 
Glass- and silicon-based microfluidic devices are usually fabricated through 
photolithography, dry/wet etching and physical/chemical deposition process. 
Other material properties that are critical to successful application of microfluidic 
devices include analyte adsorption, permeability, chemical resistance, electrical 
insulation, and hydrodynamic resistance [34]. 
 
1.4 Mobile health 
The widespread use of mobile devices has offered a novel approach to 
address many health-related challenges. The emerging mobile health (mHealth) 
technologies rely on mobile communication devices such as cell phones and 
tablets to realize remote medical diagnosis and monitoring [35]. In many regions 
of the world, medical equipment is either unavailable or insufficiently portable for 
wide and fast deployment. Meanwhile, the mobile devices and mobile networks 
can be present in these regions. According to the data released by International 
Telecommunication Union (ITU), in 2015 96.8% of the people worldwide are 
mobile-cellular telephone subscribers, and 47.2% of them are active mobile-
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broadband users [36]. The penetration of mobile devices in many low- and 
middle-income countries has surpassed many other infrastructures such as paved 
roads, electricity, and advanced healthcare resources. Such increasing 
accessibility of mobile devices can provide opportunities to transform the way 
health services and information are delivered, collected and managed. 
Smartphones have been increasingly adapted in various health care 
applications in recent years. According to the applications, the use of smartphone-
based healthcare practice can be divided into two categories: out-of-clinic use and 
in-clinic use [37]. Out-of-clinic smartphone use covers most of the software 
applications (apps) and the corresponding devices for the daily monitoring of the 
health and wellness. Smartphones can also be used to promote a healthy life style 
and help people get access to useful medical information when they need it. Built-
in sensors inside the mobile devices or external wearable sensors measure 
people’s health-related activities such as heartbeat and breathing during walking, 
running, or sleeping [38]. Unlike older generations of at-home monitoring 
equipment that require manual record keeping, these applications usually have a 
high-level of automation in terms of the recording and processing of the measured 
data, and usually the information is stored in a personalized profile that can be 
securely transmitted to a cloud center to perform processional medical analysis. 
Such applications usually present the data in an appealing graphic fashion to users 
and provide simple suggestions or conclusions. On the other hand, the in-clinic 
applications of smartphones involve the diagnostics of specific types of diseases 
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and are supposed to help make clinical decisions. Many of the tests that are 
usually exclusively performed in centralized laboratories with high-end 
instrumentation and skilled personnel can be simplified and realized with the 
smartphones. For example, a single-channel electrocardiograph (ECG) can be 
integrated at the back case of an iPhone [39]. A lead I ECG can be generated 
when patients rest the fingers of both hands on the electrodes on the rear of the 
cell phone. Although the one-lead ECG is not as comprehensive as the standard 
twelve-lead ECG for the assessment of heart function, it can perform basic heart 
monitoring in a quick and easy way. Likewise, plug-and-play blood pressure 
monitor can wirelessly connect to a smartphone [40]. Instead of simultaneously 
operating both a stethoscope and sphygmomanometer while diagnosing the 
patient, the clinician can directly obtain the data collected by smartphone and 
focus on engaging the patient talking about his or her health status. There are also 
smartphone-based instruments for microscopy, spectroscopy and solid/liquid 
phase bio-assays [41]. By utilizing the mobile devices that patients have already 
purchased for non-medical purposes, whose operation is already familiar for 
people with non-technical backgrounds, the barrier of accessing millions of 
medical instruments for the large population of people in resource-limited settings 
can be eliminated. 
Challenges for the current mobile health technologies include the 
expansion of detection capacity to complex diseases, privacy and security 
concerns, and the difficulties of regulatory approval [42].  
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1.5 Figures 
 
 
Figure 1.1: Schematic diagram of the classical PCR process. 
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Figure 1.2: Schematic diagram of the LAMP process [24]. 
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CHAPTER 2 
SMARTPHONE-BASED SYSTEM FOR HIV DETECTION 
 
2.1 LAMP assay for HIV detection 
Human immunodeficiency virus (HIV) affects about 35 million people 
worldwide [43]. During the course of nearly four decades since the emergence of 
HIV on a pandemic scale, advances in antiretroviral therapy have transformed 
HIV infection from a death sentence into a chronic illness which can have little 
impact on life expectancy for those in whom the infection is properly managed 
[44]. At the population level, rates of new infections, mother-to-child 
transmission, and deaths from HIV-related causes are declining. However, the 
availability of the appropriate diagnostic technologies essential to informing 
treatment in routine HIV care is still among the chief barriers preventing access to 
the standard of care for millions of HIV-positive individuals worldwide, 
particularly in resource-limited settings. 
CD4+ T lymphocyte counts and blood plasma viral load are the two core 
diagnostic measurements broadly considered essential to HIV care, as they both 
guide the initiation of therapy and indicate the efficacy of each individual’s 
treatment regimen [45]. CD4 counts, traditionally performed by flow cytometry, 
are increasingly available in remote settings due to the introduction of new 
portable platforms [46, 47]. Viral load platforms, on the other hand, trail CD4 
technologies in penetrating the developing world. Viral load instruments are 
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traditionally reverse-transcription polymerase chain reaction (RT-PCR), nucleic 
acid sequence-based amplification (NASBA), or branched DNA (bDNA) assays 
which require a laboratory setting, extensive sample handling, and sophisticated 
processing [48]. 
One promising solution that can help address this issue is loop-mediated 
isothermal amplification (LAMP) [49]. LAMP emerged in the early 2000s as an 
alternative to PCR for nucleic acid detection [22]. LAMP is attractive for point-
of-care applications because it does not require temperature cycling like PCR 
(isothermal at 60–65 °C), and because it is typically less sensitive than PCR to 
amplification inhibitors. Reverse transcription loop-mediated isothermal 
amplification (RT-LAMP) assays for HIV were first described quickly after the 
introduction of the initial concept [50, 51], and there have been several reports 
since then for variations of the assay, including efforts toward point-of-care 
applications [52, 53]. To date, however, an approach capable of performing a 
quantitative RT-LAMP assay from a drop of whole blood on a platform 
compatible with a fully automated, portable device has not been presented.  
Traditionally, it is believed that nucleic acid amplification requires 
complete purification of the RNA or DNA target to be compatible with the 
amplification reaction. The robustness of LAMP, however, has disrupted this 
thinking and whole blood treated only with cell lysis buffer has been employed by 
Curtis et al. for HIV LAMP in a qualitative measurement in an electricity-free 
heating device [52]. We present here RT-LAMP with minimally processed lysed 
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whole blood for a quantitative measurement of HIV viral load capable of 
detecting as few as 3 virus particles per ~60 nL reaction droplet. Our approach to 
RT-LAMP HIV viral load measurements begins with a drop of whole blood. The 
data presented here demonstrates the potential of the approach to be developed 
into a fully automated mobile device that does not require manual processing. We 
implement a simple microfluidic mixing module to show the whole blood lysis 
step can be performed on a chip without loss of analyte or interference with the 
detection assay. We then move to a microchip platform and characterize the RT-
LAMP reaction with purified RNA and lysed whole blood spiked with viral RNA, 
imaging with both a standard fluorescence microscope and a consumer 
smartphone without hardware modifications. We then integrate the microfluidic 
lysis, microchip reaction platform, and smartphone imaging to demonstrate the 
capability of our platform to quantitatively determine HIV viral load from a drop 
of blood. 
 
2.2 Smartphone-based instrumentation 
A Samsung Galaxy Note 4 smartphone was purchased for imaging of the 
RT-LAMP reaction on the microchip substrate. The smartphone hardware was not 
modified from its factory conditions. A high-pass colored glass filter with cut-off 
at 530 nm was placed between the camera and the chip to isolate the fluorophore 
emission wavelengths. A 3D-printed cradle (Figure 2.1) was designed to position 
the smartphone horizontally with the camera directly above the microchip. A 
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mounting cylinder was also 3-D printed to hold a BLUE LED which fit within the 
cradle and illuminated the microchip from an angle. A mounting cylinder was 
also 3-D printed to hold a high-output blue light-emitting diode (LED) and a 
shortpass filter with a 500 nm cut-off wavelength, which fit within the cradle and 
illuminated the microchip from an angle. The LED was powered with 3 V from 
an Agilent E364xA DC power supply with automated on/off function controlled 
with a MATLAB script. It was also determined that the Blue LED could be 
adequately powered by a standard 3 V lithium coin battery, but the DC power 
supply was used for the purpose of PC control. 
Due to biosafety considerations, the entire smartphone imaging apparatus 
was placed inside a biosafety cabinet for performing integrated measurements. 
For this reason, remote control of the imaging function was desired. The Android 
application IP Webcam23 was downloaded from the Google Play store and 
installed on the smartphone. This application transmits a live image over the 
network which can be viewed in real-time in a web browser. The browser 
interface allowed for control of the smartphone camera’s focus, exposure, and 
gain. Imaging of the RT-LAMP reaction was performed with the following 
parameters set in the IP Webcam web browser interface: 8X zoom, 99% stream 
quality, exposure compensation of 4, and “Night vision” function with a gain of 
10.00 X and exposure 10. A MATLAB script was written to automate the image 
capture process. The script was initialized simultaneously with the activation of 
the heating stage. The MATLAB script imaged the reaction in the following 
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manner: blue LED was switched on, delay 3 s, capture image from IP Webcam 
web browser interface, delay 2 s, and finally switch off blue LED. This process 
was repeated every 30 s while each reaction was imaged. 
A silicon microchip was used for RT-LAMP experiments. Briefly, a 
silicon wafer was thermally oxidized to create a silicon oxide layer of ~150 nm. 
The oxide is then patterned with photolithography and hydrofluoric acid etch step, 
exposing the silicon where the wells will be etched. The wafer was then immersed 
in a heated Tetramethylammonium hydroxide (TMAH) bath for 18 hours to 
anisotropically etch the silicon, creating inverted square pyramids for later use as 
reaction wells. Chips for all on-chip RT-LAMP experiments were prepared in the 
following manner: First, the microchip was cleaned in a piranha solution 
containing 1:3 30% hydrogen peroxide and sulphuric acid for 10 min and then 
rinsed in deionized water. Each chip was then degreased with acetone, methanol, 
and isopropanol and dried by blowing with nitrogen gas. To produce a 
hydrophobic surface to promote stability of droplets, the chip was rinsed with 
Sigmacote® from Sigma-Aldrich by pipetting the solution repeatedly over the 
surface of the chip. The chip was then rinsed briefly with isopropanol, dried by 
blowing with nitrogen, and placed in a copper bowl. 
A Narishige IM-300 Microinjector with Eppendorf VacuTip 
microinjection holding capillary (15 µm inner diameter, 100 µm outer diameter) 
was used both to spot primers and place reaction droplets. A 20 ms injection pulse 
was used resulting in a droplet of approximately 60 nL. The microinjection 
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procedure was performed after chip cleaning and preparation as follows: LAMP 
DNA primers in TE buffer were diluted in water to the final reaction 
concentration. Droplets were placed in all 36 wells of the microchip array using 
the microinjection system and a 3D micromanipulator (MCL-D331) from World 
Precision Systems. The process was visualized with a Leica MZFLIII microscope. 
Droplets containing primers were allowed to dry completely, leaving dehydrated 
DNA LAMP primers in the reaction wells. Following visual confirmation that all 
droplets had dehydrated, the chip was submerged in heavy mineral oil (Fisher) 
and placed in a desiccator to remove air bubbles. The primary function of the 
mineral oil is to protect the reaction droplets from evaporation during heating at 
65 ºC. 
During degassing, the primer-less RT-LAMP reaction was prepared and 
transferred to the microinjection capillary. Reaction droplets were then placed in 
each well by lightly contacting the bottom of each reaction well, injecting a 
droplet of approximately 60 nL, and lifting the capillary out of the oil. The chip 
containing all 36 droplets submerged in oil in the copper bowl was then 
transferred to the heating stage and imaging apparatus (fluorescence microscope 
or smartphone apparatus). 
 
2.3 Experiment results 
The samples used in this experiment were whole venous blood samples 
that were drawn from HIV-negative donors with a syringe and HIV-1 IIIB virus 
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propagated in the H9 human T lymphocyte cell line. HIV-1 RNA was purified 
from HIV-1 IIIB whole particles using the PureLink® Viral RNA/DNA Mini Kit 
from Life Technologies. The master mix of RT-LAMP contains reaction buffers, 
enzymes, and primers. Viruses were spiked into lysed blood following the mixing 
to keep the virus concentration identical between samples. 
The RT-LAMP was demonstrated on a microchip in a microfabricated 
silicon micro-well array. All on-chip RT-LAMP measurements were prepared 
with DNA LAMP primers pre-spotted and dehydrated on the chip prior to oil 
immersion, degassing, and reaction droplet placement. Initially, purified RNA in 
water was characterized on the chip. Figure 2.2a displays fluorescence curves 
measured with a fluorescence microscope, while Figure 2.2b shows the threshold 
time analysis. Threshold time for each individual reaction was approximated from 
baseline-subtracted fluorescence curves by determining the measurement time at 
which the signal exceeded 20% of the maximum fluorescence value it achieved 
during the course of the entire measurement. In this measurement, data from 6 
droplets total were removed due to outlying behavior believed to be due to 
contamination, experimenter error, or because no reaction was observed. The 
analysis includes one of six reactions in each of the 102-103 (yellow) and 101-102 
(green) vp/RXN samples, and four of six reactions in the 100-101 (blue) vp/RXN 
sample. In Figure 2.2c-f, lysed whole blood spiked with viral RNA was imaged 
with the smartphone apparatus as described in the experimental section. Whole 
viruses were not used in this measurement as the apparatus had not yet been 
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converted to be contained within a biosafety cabinet. Figure 2.2c shows 
fluorescence curves gleaned from the smartphone images, Figure 2.2d shows the 
threshold time analysis, and Figure 2.2e shows examples of the smartphone 
fluorescence images every minute for minutes 7-11. Four of the six reactions for 
the sample at approximately 101 vp/RXN (green) were omitted because they did 
not react before 30 min. Figure 2.2f shows an endpoint measurement obtained 
following termination of the real-time monitoring at 30 min. Four additional 
droplets in the array had reacted before the image in Figure 2.2f-i was captured 
with the fluorescence microscope. Figure 2.2f-ii is an additional smartphone 
image captured shortly after the microscopy image was obtained. Figure 2.2f-iii is 
identical to Figure 2.2f-ii with an additional overlay color-coded consistent with 
the color-concentration convention used throughout this work, from left to right: 
red for concentrations of 104-105 vp/RXN, orange for 103-104, yellow for 102-103, 
green for 101-102, and blue for 100-101 vp/RXN. The sixth column on the far right 
is a negative control containing blood sample and reaction mix without viral 
RNA. Finally, Figure 2.2f-iv is a colormap rendering of Figure 2.2f-ii produced in 
MATLAB as an example of the image analysis process. 
Integrated experiments were designed to demonstrate the full capacity of 
this approach for a sample-to-answer solution to point-of-care HIV viral load 
quantification. The complete flow of the experiment is depicted in Figure 2.3a. 
These experiments differed from other measurements presented in this work in 
that whole blood samples were spiked with “live” HIV-1 IIIB virus particles (not 
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viral RNA) at a range of concentrations and each individual sample was analyzed 
on a separate chip. Of the 36 wells on the micro-chip array, 6 were used for 
negative controls and up to 30 were used to test the sample. 
Five samples were tested (named A-E), containing approximately 32,000, 
3,200, 320, 32, and 3.2 virus particles per reaction, respectively. Since each 
reaction droplet contains approximately 4.8 nl of whole blood, this corresponds to 
viremias in the range of 6.7 × 105 – 6.7 × 109 viruses per mL of blood, or 1.3 × 
106 – 1.3 × 1010 RNA copies per mL of blood plasma (assuming 45% 
haematocrit). 
Due to biosafety considerations, the entire process was adapted as 
described in the experimental section to be contained within a biosafety cabinet. 
This introduced challenges to droplet placement, which was performed with a 
motorized micromanipulator controlled with a joystick and guided by a video feed 
from a small table-top microscope. Decreased control over droplet placement led 
to a decreased success rate in droplet placement. As a result, not all of the thirty 
wells designated for a virus-positive reaction droplet were used in every 
measurement. The number of successfully placed droplets for samples A through 
E was as follows: 29, 28, 30, 22, and 22. 
Figure 2.3b shows the fluorescence curves, measured with the smartphone 
system, for all droplets which amplified within 30 min. Figure 2.3c shows the 
threshold time vs. virus number. The slope of the fit to threshold time vs. virus 
number is -1.9993, which differs in magnitude by 98.0% compared to on-chip 
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RNA in lysed whole blood, 13.9% compared to on-chip RNA in water, 18.5% 
compared to virus particles in whole blood in the thermocycler, and 25.9% 
compared to purified RNA in water (method 2) analysed in the thermocycler. In 
Figure 2.3d, we consider a new metric, which is amplification efficiency, and 
observe a trend between virus number and the fraction of droplets which 
amplified. A framework for understanding this phenomenon in the context of 
digital LAMP measurements is described in the next section. 
The replacement of laboratory hardware (e.g. thermocycler fluorescence 
detection or fluorescence microscope) with a common smartphone is a core aspect 
of the novelty of this research. First, it demonstrates that the lysed blood RT-
LAMP measurement can be performed with existing mobile technology that is at 
least as affordable as a high-end smartphone. Furthermore, trends suggest that 
mobile communications technologies will continue to improve in capabilities and 
decrease in cost, an exciting outlook for fluorescence and other optics-based 
point-of-care diagnostics. Second, our platform, consisting of a 3-D printed 
platform, LED light source, emission filter, and small form-factor heating stage 
suggests that, if adequately robust, an add-on component may be developed as an 
attachment to existing smartphones, shifting the computation and imaging burden 
from components integrated with the diagnostic platform to a consumer item that 
is becoming ubiquitous, even in resource-limited settings [54]. This could 
significantly reduce the production and deployment costs of such a technology. 
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2.4 Figures 
 
 
Figure 2.1: The instruments for smartphone-based HIV detection.  
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Figure 2.2: On-chip RT-LAMP for HIV-1 detection using smartphone. 
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Figure 2.3: Integrated RT-LAMP detection of HIV-1 in lysed whole blood. 
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CHAPTER 3 
SMARTPHONE-BASED SYSTEM FOR MULTIPLEXED DISEASE-
SPECIFIC NUCLEIC ACID SEQUENCES DETECTION 
 
3.1 Introduction 
Infectious diseases, such as HIV/AIDS, tuberculosis, and malaria, while 
accounting for less than 10% of deaths in the developed world, are responsible for 
more than half of all deaths in developing countries [2]. A contributing factor to 
the mortality of infectious diseases in developing countries is that co-infection by 
more than one pathogen carries greater risk than a single infection, while many 
assays that only test for one agent could miss the presence of a co-infection. 
Despite recent progress in the development of new drugs for treatment of viral, 
bacterial, and fungal infections [55], the worldwide death toll continues to rise 
with critical needs for increased understanding of fundamental disease 
mechanisms, and enhanced point-of-care diagnostics. Importantly, there is a need 
for improved surveillance tools that can detect the emergence of drug-resistant 
strains, alert clinicians to the initiation of a potential outbreak, monitor the 
effectiveness of quarantines, and facilitate cross-communication between 
clinicians that are geographically distributed. For human infectious diseases in the 
US, approximately 55 are designated as “reportable” by the Centers for Disease 
Control, which requires a positive laboratory test to be communicated to central 
authorities, enabling the information to be reported to clinicians by the National 
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Notifiable Diseases Surveillance System (NNDSS), which is most heavily utilized 
only for the most deadly disease outbreaks [56].  Most forms of influenza have no 
reporting requirement, and thus no information is currently gathered or 
communicated for human respiratory infectious diseases that are responsible for 
2-3 million cases and 250,000 – 500,000 deaths worldwide each year [57].  
Reporting requirements are even more rudimentary in the developing world, 
leaving clinicians largely unaware of the global view of incidence, spread, and 
control of infectious disease that affects their community. 
The societal and economic toll of infectious disease is not limited to 
human populations.  Animals raised for human consumption live in facilities in 
which large herds share ventilation, feed, and waste handling within confined 
spaces in which respiratory infectious disease can spread rapidly. Similar 
concerns exist for companion animals and racing animals, particularly for those 
with high economic value.  In veterinary medicine in the US, only a handful of 
infectious diseases are categorized as “reportable” by the USDA, requirements 
vary from state to state, and no cross-communication infrastructure exists that 
enables veterinarians to easily share results with each other. 
A key characteristic for a successful system for detection and reporting of 
infectious disease is speed.  For example, modeling studies on various 
intervention strategies for pandemic influenza response have shown that the 
highest impact on attack rate is obtained by identification and initiation of 
treatment one day earlier [58]. Particularly for point-of-care scenarios, where the 
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clinician is testing a patient at a remote clinic, a farm, or a racetrack, the need to 
send samples to a central laboratory, to wait for the test to be performed, and to 
wait for the results to be reported, results in an enormous waste of opportunity to 
determine if aggressive treatment or quarantine is needed before the disease 
spreads further.  The ability to rapidly share the results of positive and negative 
tests can revolutionize the manner in which infectious diseases are managed.  
Therefore, it is of paramount importance for the test to be performed at the same 
location as the patient, so action can be taken within the same day as the sample is 
gathered. 
Taking advantage of the fact that bacteria and viruses have distinct genetic 
components that are represented by unique nucleic acid sequences, the most 
commonly used laboratory analysis technique used for diagnosis of infectious 
disease is the Polymerase Chain Reaction (PCR) [59-61].  PCR enables sequence-
specific concentration amplification of infectious disease DNA through a series of 
thermally cycled chemical reactions between a set of enzymes, a prepared test 
sample (of DNA extracted from a pathogen-containing bodily fluid), and disease-
specific “primer” molecules.  PCR primers for detection of every common human 
and animal infectious disease have been identified, and may be inexpensively 
synthesized through readily available commercial sources. Conventional PCR 
amplification requires expensive laboratory-based instruments that are operated 
by technicians and housed in central facilities, although there have been strong 
efforts aimed at miniaturization of PCR for translation closer to the point of care 
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through the engineering of systems integrated into a small chip or cartridge [59, 
61-89]. Many of these efforts have aimed at accelerating the thermal cycling 
process through reduction in the liquid volume  [70, 74, 79, 80, 83, 85, 88, 90-93], 
while others have explored various modalities for sensing the presence of the 
amplified product using biosensors [94-98].  Due to the cost and complexity of 
implementing thermal cycling (generally between 95 °C (denaturation), 72 °C 
(extension), and 68 °C (annealing) with ~30-40 cycles), various isothermal 
nucleic acid amplification methods have been proposed and demonstrated with 
comparable sensitivity to PCR [99-101], but with a requirement to more fully 
customize and validate the primer sequences. Of these, loop-mediated isothermal 
amplification (LAMP) has emerged as a compelling approach for portable 
applications [102-104].  Details of the LAMP process, primer design, and 
example applications are thoroughly explained in [105]. 
An important prerequisite for the widespread adoption of point-of-
care (POC) tests is the availability of detection instruments that are 
inexpensive, portable, and able to share data wirelessly over the internet 
[106-110]. Due to the rapid development of computational, communication, 
and sensing capabilities of smartphones since the introduction of the iPhone 
in 2007, these devices have become similar to personal computers with 
integrated cameras, geolocation capabilities, and access to cloud services.  
Since 2011, over 478 million smartphones are sold annually, with that 
number expected to double in the next 4 years [111], making them a nearly 
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ubiquitous tool that can be adapted to performing POC tests. Recent 
examples include attachments that enable smartphones to serve as 
stethoscopes [112], ultrasound probes [113], microscopes [114], fluorescent 
microscopes [115, 116], label-free biosensor detection instruments [117, 
118], fluorimeters [119], and colorimetric assay readers [120]. Portable 
detection systems for infectious disease are already recognized as a likely 
extension of mobile technology [102, 121-126], and a PCR or LAMP 
mobile sensing platform that is integrated with a smartphone and a smart 
service system for reporting and sharing results with a network of users is 
highly desirable. 
In this work, we have developed a smartphone-based portable detection 
instrument to perform isothermal LAMP-based analysis for the diagnosis of 
equine respiratory infectious diseases. While our ultimate goal is the diagnosis 
and mobile reporting of human infectious diseases, we initially focus specifically 
upon equine respiratory infections due to their economic importance to the horse 
racing industry, similarity to the tests that would have an impact upon the food 
animal industry, and the strong need for a service system that can inform 
networks of field veterinarians. Our work involves the development of a 
microfluidic approach for identifying the presence of specific nucleic acid 
sequences from the pathogens of equine respiratory infections using a portable 
detection system integrated as a disposable cartridge that can be read by a 
conventional smartphone in conjunction with a custom-designed cradle. Capable 
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of simultaneously performing 10 parallel isothermal amplifications (with two 
utilized for experimental controls and eight for pathogen-specific DNA detection 
assays), the system can detect target DNA sequences from more than one 
pathogen with a single test protocol, and interface with a smartphone app that 
communicates with a cloud-based service for the immediate reporting of the 
location, time, identity, and results (positive and negative) of the detection. In this 
paper, four LAMP-based assays have been developed for the detection of four 
important	 equine respiratory infectious pathogens:  streptococcus equi (S. Equi), 
strangles (streptococcus zooepidemicus, abbreviated as S. Zoo), equine 
herpesvirus type 1 and type 4 (EHV-1 and EHV-4). The smartphone-based 
detection demonstrates the same detection limits and sensitivity as LAMP 
reactions performed on commercially available laboratory-based systems, and is 
capable of identifying the specific nucleic acid sequences of pathogens for both 
single-infection and co-infection scenarios. To our knowledge, a smartphone-
based nucleic acid testing approach for the diagnosis of veterinary infectious 
diseases has not been reported in previous literature.    
Our approach utilizes a silicon microfluidic chip with LAMP primers 
applied to individual assay lanes, which is embedded within a credit card format 
plastic holder to facilitate handling and to carry assay-specific information.  The 
chip accepts a single droplet (~15 µL) test sample that is distributed between 10 
separate regions. After a ~30 min LAMP reaction (conducted on a hotplate, 
separate from the phone), the plastic card is inserted into a slot in the body of a 
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cradle (in the same manner as chip readers used for modern credit cards) that 
places the chip in contact with a heater from below, while illuminating with LEDs 
from above. The cradle accepts an unmodified smartphone, placing the chip in 
front of its rear-facing camera, which gathers a fluorescent image of the assay 
lanes through a macro lens (to increase field of view) and an optical emission 
filter. Image processing software operating on the smartphone automatically 
recognizes the regions of interest within the fluorescence image that correspond to 
the relevant assay lanes, and determines a fluorescent intensity value for the 
positive control, negative control, and each assay. The system reports normalized 
fluorescent endpoint intensity values of each lane and generates a 
positive/negative determination for each assay in ~5 s.  The software application 
operating on the smartphone gathers information about the tests conducted on the 
microfluidic card, patient-specific information, and results from the assays that 
are communicated to a cloud storage database.  Although not the focus of the 
results presented here, the database anticipates queries from a network of 
geographically distributed users who seek updates when positive tests are 
recorded within user-defined constraints (such as geographic area, disease, animal 
category, or date) and the ability to graphically represent trends such as temporal 
sequences of positive tests overlaid with location, and trends over time.  We 
anticipate that a smart service system for clinicians would also facilitate 
messaging between users to easily share information such as specific 
circumstances of tests and the outcomes of treatment.  Integration of a 
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smartphone-based testing capability and smartphone-based epidemiology 
capability represents a future goal of the sensing capability reported here. 
 
3.2 Experimental 
3.2.1 Chip substrate fabrication 
To perform multiplexed LAMP detection of pathogen-specific nucleic acids, a 
silicon-based microfluidic chip with 10 parallel flow channels and a shared 
sample inlet was designed and fabricated. The chip is the size (25 mm × 15mm) 
of a standard SIM (subscriber identity module) card. Flow channel dimensions are 
10 mm in length, 500 µm in width and 200 µm in depth, representing a volume of 
1 µL each. The inlet of the chip is a 4 mm entrance chamber that feeds its 
contents to 10 parallel assay channels. Two square markers at the opposite end of 
the chip are used for position alignment during fabrication and for automated 
image recognition during the assay measurement. The fabrication process for the 
microfluidic chip is illustrated in Figure 3.1a. A 4-inch <100> silicon wafer 
(University Wafer, South Boston, MA) with one side polished is thoroughly 
cleaned and used as the substrate in the photolithography process. Positive 
photoresist SPR 220 (MicroChem, Newton, MA) is spin-coated on the polished 
side of the wafer to form a 4.5 µm covering layer, followed by a soft-bake at 60 
°C for 2 min and 110 °C for 1 min. The photoresist is then exposed with an i-line 
(365 nm) mask aligner (EVG 620) with an expose dose of 180 J/cm2. The 
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exposed regions of the photoresist with the outline of the microfluidic pattern are 
subsequently removed by immersing the wafer in AZ developer diluted 1:4 with 
deionized (DI) water for ~4 min. The photoresist in the unexposed regions is 
solidified though a hard-bake at 110 °C for 1 min. For the anisotropic etching of 
the silicon substrate, a Bosch process with alternating steps of SF6/O2 etching and 
C4F8 passivation is used to create 200 µm deep trenches in an inductively coupled 
plasma reactive ion etcher (ICP-RIE). After the Bosch process, the remaining 
photoresist was stripped with acetone and O2 plasma cleaning, leaving the bare 
silicon exposed. Because bare silicon has been reported to have inhibitory effects 
on nucleic acid amplification due to absorption of polymerase [61], the wafer was 
thermally oxidized in a furnace (1150 °C) for 2 hours to grow a 200 nm film of 
SiO2. The final step of the chip fabrication is to dice the wafer into individual 
chips (Figure 3.1b). The scanning electron micrograph (SEM) in Figure 3.1c 
shows the vertical sidewalls of the etched channels. 
 
3.2.2 Chip preparation and sealing 
Before preparing them for assays, microfluidic chips are stored under vacuum in a 
desiccator after being thoroughly cleaned with piranha solution, a mixture of 98% 
sulfuric acid (H2SO4) and 30% hydrogen peroxide (H2O2) at the ratio of 3:1, 
rinsed with distilled water (DI) and then dried with nitrogen gas. For the on-chip 
experiments, an adhesive membrane and a glass coverslip are used to prevent 
evaporation of the reaction solution in the flow channels during heating at 65 °C. 
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The chip is covered with a transparent double-sided adhesive (DSA) (ARseal™ 
90880, Adhesives Research) with laser-machined holes after the deposition of 
primers into the channels. The holes are cut to match the position of inlets and 
ends of the channels at the substrate, to allow for displaced air venting during 
injection of the test sample. The holes are also used to inject LAMP primers 
individually into each lane, as discussed in section 3.2.3. Figure 3.1d shows the 
deposition process for the four types of primers and two experiment controls. The 
DSA forms a barrier to evaporation or cross-contamination, and it is compatible 
with the reagents used in the amplification reaction. After the reaction solution is 
injected into the channels, the chip is sealed with a glass coverslip (GOLD 
SEAL® 63760-01, Electron Microscopy Sciences) by peeling off the top covering 
layer of DSA and binding it with the coverslip. The binding is robust enough to 
effectively prevent the entrance of air into the flow channels from the surrounding 
environment.   
The chip is housed within a plastic laminated holder that is in the shape of 
a credit card (85.6 mm × 54.0 mm × 0.8 mm). The holder is designed to handle 
the small microfluidic chip during the measurement on the smartphone-based 
instrument preventing the user from touching the chip, and to provide a surface 
upon which barcoded information about the included assays can be printed. 
Polyoxymethylene (POM) is selected as the card material because of the low 
auto-fluorescence, low cost, and excellent dimensional stability. After the on-chip 
amplification reactions start and reach the plateau stage, the chip is placed inside 
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the card and loaded into the cradle for the scanning of the quick response (QR) 
code and for the multiplexed reading of 10 assay lanes. Information about the on-
chip detection including the serial number of the chip, primer deposition date and 
assays in each channel can be provided by the holder card.  
 
3.2.3 Primer deposition 
The primers are uniformly deposited onto the surfaces of the flow channels before 
sample loading through the pipette injection at the endpoint of each channel. 
Channel 1 serves as the positive control by depositing a mixture of the primer set 
and template DNAs for S. Zoo, while channel 2 serves as the negative control 
because no primers are deposited within it. The remaining eight channels are 
divided into four groups to allow for the deposition of four types of primer sets 
used in this work, with channels 3 and 4 prepared with primers for the S. Equi 
assay, channels 5 and 6 deposited with primers for the S. Zoo assay, channels 7 
and 8 deposited with primers for the EHV-1 assay, and channels 9 and 10 
deposited with primers for the EHV-4 assay. The primer solution injected into the 
eight channels is prepared with a direct 20-fold dilution of the corresponding 
primer solution (originally at 55µM) in nuclease-free water, giving a final primer 
concentration of 2.75 µM. For the solution injected in the positive control 
channel, 1 µL of the S. Zoo DNA sample solution at a concentration of 5×106 
copies/mL is mixed with 1 µL of 20 times diluted 55µM S. Zoo primer solution to 
make a 2 µL final solution. After the solutions are prepared, a volume of 1 µL of 
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each solution is taken by a pipette and injected into the corresponding flow 
channels from the end of each channel. The injected liquids flow along the etched 
trench reaching the opposite end of the flow channel without entering the 
common inlet hole. Due to the small volumes, all the primers completely dry on 
the channel surface at room temperature within a few minutes. The primer 
deposition process enables batches of chips to be prepared in advance and stored 
for later use. 
 
3.2.4 LAMP assay development 
We have developed four specific LAMP assays to demonstrate the functionality 
of the smartphone-integrated instrument for the multiplexed detection of 
pathogen-specific nucleic acid sequences. Streptococcus Equi (ATCC® 9528™), 
Streptococcus Zooepidemicus (ATCC® 39920™), Equine Herpesvirus-1 (USDA 
040-EDV), and Equine Herpesvirus-4 (USDA 044-EDV) were chosen as the 
pathogens of interest due to their widespread virulence among horse populations. 
The S. Equi and S. Zoo bacteria are received in lyophilized form and are 
propagated in bovine-brain heart infusion medium (Sigma Aldrich) for a period of 
16 hours to obtain a carrying concentration of 1×108 colony forming units 
(CFU)/mL. Glycerol stocks are prepared from this concentration and are stored at 
-80 °C until needed for experiments. The Equine Herpesvirus-1 and Equine 
Herpesvirus-4 stocks are aliquoted into smaller volumes and also stored at -80 °C 
until needed. DNA from all the pathogens are extracted via a standard heat-lysing 
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protocol as described earlier [127]. The extracted DNA is quantified using PCR 
standard curves that were established using synthetic targets.  
A 25 µL LAMP reaction mix contains the following: 3.5 µL of 10mM 
dNTPs (New England Biolabs), 2.5 µL of 10X Isothermal Amplification Buffer 
(New England Biolabs), 2 µL of 5M Betaine (Sigma Aldrich), 1.5 µL of 100 mM 
Magnesium Sulfate Solution (New England Biolabs), 2 µL of primer mix, 2 µL of 
8000units/mL Bst 2.0 Warmstart DNA Polymerase (New England Biolabs), 1.25 
µL of 20X Evagreen Dye (Biotium), 2.25 µL of DEPC-treated water (Invitrogen), 
and 8 µL of the template DNA. The LAMP reactions are validated on a benchtop 
thermocycler (Eppendorf Realplex Thermocycler) at 65 °C for 40 min and 
terminated by heating at 85 °C for 5 min.  The 25 µL reaction mix is divided into 
three equal parts (8 µL) for triplicate repetition. Ten-fold serial dilutions of the 
extracted DNA are carried out in DEPC-treated water to determine the working 
range of our LAMP assays.  
Novel LAMP primers were designed for S. Equi and S. Zoo, targeting the 
seM and sorD genes respectively. The target sequence for S. Equi was obtained 
from the NCBI database using GenBank AJ249868.1 and U73162.1. The target 
sequences for S. Zoo were also obtained from the NCBI database using GenBank 
CP002904.1, NC_011134.1, and FM204884.1. LAMP primers were designed 
using Primerexplorerv4 (https://primerexplorer.jp/e/). LAMP primers for EHV-1 
and EHV-4 were utilized from the sequences reported by Nemoto et al [128]. All 
LAMP primers were synthesized by Integrated DNA Technologies (IDT DNA) 
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and are listed in Table 3.1. Briefly, each primer mix consists of 0.2 µM of F3 and 
B3, 1.6 µM of FIP and BIP, and 0.8 µM of Loop F and Loop B primers.  
 
3.2.5 Smartphone-based instrument 
The smartphone-based instrument to measure the fluorescent emission from the 
on-chip LAMP reactions is shown in Figure 3.2. The system consists of a 
smartphone phone (Nexus 6; Motorola, IL, USA) and a 3D-printed plastic cradle 
body that contains the optical and electrical components to excite and collect 
fluorescence signals at a constant, controlled temperature. The top part of the 
cradle interfaces with the rear-facing camera of a Motorola Nexus6 smartphone 
(13 megapixels, pixel size of 1.4 µm). The cradle aligns the smartphone camera 
with the internal optomechanical components, and also serves as a dark chamber 
for fluorescence detection by excluding external light. A schematic of the 
fluorescence imaging system is depicted in Figure 3.2a. When the mobile phone is 
slid into the slot at the top of the cradle, the rear-facing camera is aligned over a 
window (30 mm) that is formed by a long pass filter (525 nm, Edmund Optics, 
#84-744) and a macro lens (12.5X, TECHO, #TECHO-LENS-01) in series. The 
long pass filter is selected according to the emission wavelength of the fluorescent 
dye used in the LAMP assay.  The macro lens placed in front of the camera 
facilitates close-up photography of the chip, allowing the reduction of the distance 
between the camera and the chip to 50 mm while keeping the field of view as 
large as 24 × 24 mm with negligible barrel distortion. A light source module 
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composed of eight blue light-emitting diodes (LEDs; λpeak = 485 nm, view angle: 
135°, luminous flux: 45 lm/W, Cree Inc., #XPEBBL) and four short pass filters 
(490 nm, Asashi Spectra, #ZVS0510) that cover each pair of LEDs is installed at 
the upper corners of the cradle to provide the excitation illumination that does not 
spectrally overlap with the dominant fluorescence emission wavelengths. The 
LEDs are mounted on a custom-built printed circuit board (PCB) and arranged 
with square symmetry to support uniform illumination over the whole chip area. 
The light source module is powered by two AAA batteries and operated using an 
on/off control switch. A positive temperature coefficient (PTC) heater (12V-80 
˚C; Uxcell, Hong Kong, China) is placed beneath the chip, maintaining the chip 
65 ˚C without an additional temperature controller. The PTC heater is made from 
specific ceramic materials that have a highly nonlinear thermal response and a 
positive thermal coefficient of resistance. When the temperature of the heater 
exceeds a composition-dependent threshold, the electrical resistance increases 
resulting in decreased heat output to set the temperature at a predefined limit. The 
installed PTC heater is powered by a standard 9 V battery to set the temperature 
of the microfluidic chip around 64~ 66 ˚C during the measurements and operated 
using an on/off control switch. The overall dimensions of the cradle are ~ 90 × 70 
× 95 mm3.   The purpose of the PTC heater is not to provide thermal energy for 
the LAMP reaction, but to maintain the chip at an elevated temperature during 
fluorescence imaging, in which fluorescent background intensity is reduced 
compared to room temperature, which increases signal-to-background 
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measurement of the LAMP assays.  Thus, extended heating and precise 
temperature control are not required.  The cost of the components used to 
construct the instrument is approximately $550, and the system weight is 
approximately 15 ounces, not including the phone. 
  
3.2.6 Fluorescence microscopy 
To verify correct performance of the LAMP assay by an independent instrument, 
fluorescence microscopy was used to capture the real-time images of the on-chip 
LAMP reactions under a Nikon Eclipse FN1 fluorescence microscope with a 2× 
objective and a Nikon 96311 B-2E/C FITC fluorescence filter. While the 
smartphone assay reader is intended only to measure assay endpoints, the 
fluorescence microscope enables real-time visualization of the LAMP reaction.  
For fluorescence microscopy analysis of the chip, the sealed chip is placed on an 
INSTECT mK1000 heating stage located under the microscope objective. The 
field-of-view of the objective is large enough to measure the fluorescence output 
from only six channels of the microfluidic chip at the same time. NIS Elements 
software provided by Nikon is programmed to capture fluorescence images at 1 
min intervals with 9.6× gain and 1 s exposure time. 
 
3.2.7 Image analysis and app development 
The fluorescence images of the chip are captured by the smartphone in JPEG 
format, for analysis by an Android app developed to support this project. The 
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image is comprised of a 3120 × 4160 × 3 matrix. The first two dimensions 
represent the size of the image, and the last dimension provides a 24-bit RGB 
(red, green, blue) color space. The RGB intensity components for each pixel are 
stored as an 8-bit unsigned integer ranging from 0 to 255. Since the fluorescence 
emission from the microfluidic chip is green, centered at λ=530 nm, only the G 
channel intensity is used in the following image processing. The region of interest 
for each of the 10 lanes can be derived through a boundary detection method 
(Figure 3.3) [129-137]. Within each lane’s region of interest, covering a span of 
40×700 pixels, the average and standard deviation of all the pixel intensities are 
calculated. The average intensity obtained from the negative control (lane 2) 
indicates the background intensity. Due to a combination of factors that include 
the weak fluorescence of unbound dye and the unfiltered reflected light, the 
intensity measured in the negative control lane is used as a baseline that is 
subtracted from the measured output intensity of all the other lanes.  The image 
processing performed by the app reduces each lane to a single intensity value, 
representing the average fluorescent intensity within the region of interest, minus 
the average fluorescent intensity of the negative control lane. 
The series of images measured by the fluorescent microscope were saved 
as grayscale TIFF files. These images were imported into Matlab as a 1024×1280 
matrix of 16-bit unsigned integers (range 0-65535). Limited by the field-of-view 
of the objective, only six of the ten lanes can be monitored at once as shown by 
Figure 3.4. The average pixel intensities in the regions of each lane are calculated 
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and recorded. Since the image frames are taken at 1 min intervals, the variation of 
the average intensities of the six lanes can be plotted as a function of time to 
generate the fluorescence amplification curves.    
 
3.3 Results 
3.3.1 Off-chip characterization of the LAMP assay 
In order to determine the limit-of-detection for the four developed LAMP assays 
and to validate the specificity of the primers to the target DNA sequences, the 
LAMP reactions were characterized in a standard benchtop thermocycler 
apparatus (Eppendorf MasterCycler RealPlex4). The thermocycler carries a fast 
96-well heating block and utilizes fixed 96 LEDs to generate light for 
fluorescence excitation. Figure 3.5 (a-d) shows the baseline-subtracted 
amplification curves for the off-chip LAMP assay of S. Equi, S. Zoo, EHV-1, and 
EHV-4 using purified DNA templates, in which a series of target DNA 
concentrations spanning 3 to 6 log concentration range were tested one at a time. 
For the test at each concentration range, the LAMP reaction mixture was allocated 
into three thermocycler tubes to replicate the detection with a volume of 8 µL in 
each tube. The lower limits-of-detection are 5×104 copies/mL for S. Equi, 5×103 
copies/mL for S. Zoo and EHV-1, and 1×103 copies/mL for EHV-4. Considering 
the volume of each reaction channel is 1 µL, there are only 1-10 genome copies of 
the DNA template in the reaction at the limit-of-detection. Target DNA sequence 
with the concentration below the limit-of-detection cannot be detected through the 
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amplification reaction. A good linear fit was observed for assays between the log 
of the target DNA concentration and the threshold time of the amplification, 
which was recorded as the time taken for an amplification curve to reach 20% of 
the maximum intensity, indicating good amplification efficiency of the LAMP 
assays. To demonstrate the specificity of our LAMP assays, which is critical to 
the multiplexed on-chip detection, each of the four target DNA sequences were 
tested against non-specific primer sets (Figure 3.6). Specific template-primer 
amplification is observed for all four assays. The results are summarized in Table 
3.2. 
 
3.3.2 On-chip characterization of the LAMP assay 
Figure 3.7 (a-e) summarizes results from on-chip characterization of the S. Zoo 
LAMP assay. The fluorescence microscope was used to monitor the reactions 
within six channels in real-time for 60 min after introduction of the test sample to 
the inlet of a primer-prepared chip. We initially performed a negative control test 
as shown in Figure 3.4a, where deionized (DI) water was used as the test sample, 
and no S. Zoo DNA were included in the reaction reagents. As shown in Figure 
3.4a, no amplification occurs.  Similarly, no amplification was observed with a 
DNA concentration at 5×103 copies/mL (Figure 3.4b). When the DNA 
concentration increases to 5×104 copies/mL, all 6 lanes are observed to start 
amplification reactions within 60 min, and 3 of the 6 lanes reach saturated 
fluorescent response by 30 min. Therefore, we estimate that the limit of detection 
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for the on-chip S. Zoo LAMP assay is 5×104 copies/mL. As the DNA 
concentration is further increased to 5×105 and 5×106 copies/mL, all the lanes 
provide uniform amplification within 20 min, as shown in Figures 3.4 (d-e). The 
identical protocol was performed to characterize the on-chip detection limit for 
the S. Equi, EHV-1 and EHV-4 assays (Figure 3.8, Figure 3.9, and Figure 3.10), 
for which we obtained detection limits of 5×104 copies/mL, 5×103 copies/mL and 
5×103 copies/mL, respectively.  This set of experiments shows that the on-chip 
LAMP assay, measured via the smartphone instrument, provides similar detection 
limits as the same assay performed in the conventional off-chip format, using a 
commercially available instrument.  
 
3.3.3 Detection of target DNA sequence in the presence of non-target 
sequences 
The following experiments were designed to demonstrate the ability of this 
approach to detect viral and bacterial DNA in the presence of interfering non-
target DNA. Four types of primers used in the four developed LAMP assays and 
the positive control mixture were deposited within the microfluidic channels 
according to the method described in section 3.2.3. Here, we utilized eight assay 
wells to detect four target DNA sequences, with two replicate lanes for each 
sequence.  When pathogen-specific target DNA sequences are present in the 
sample injected into the microfluidic chip, the corresponding two channels as well 
as the positive control channels will generate an amplification reaction with 
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associated fluorescent emission, while the other lanes remain dark. By measuring 
the fluorescence output from each channel using the smartphone-based instrument 
and the software application, detection results can be quickly analyzed and 
displayed.  
Figure 3.11 shows the results for the four experiments performed for the 
detection of each of the four types of pathogen-specific DNA sequences. For the 
experiment shown in Figure 3.11a, the sample loaded into the chip contains 5×107 
copies/mL of S. Equi DNA. As seen in the fluorescence image, lanes 3 and 4, 
where the S. Equi primers are located, become as bright as the positive control 
(lane 1).  To quantitatively analyze the fluorescence image, the average intensities 
of the ten lanes, as processed in the method described in section 3.2.7, are 
calculated. Here, we designate a threshold value, half of the intensity of the 
positive control, as the value that is used to differentiate a positive test (target 
DNA present) from a negative test (target DNA not present). As shown in the bar 
graph in Figure 3.11a, only the intensities of lane 3 and 4 are significantly higher 
than the threshold, while the intensities of all the other lanes are well below the 
threshold. The variation in the intensities of the negative lanes for lanes 5 to 10 is 
due to the difference in the background intensity of LAMP assays and the spatial 
variation of LED illumination. The error bar in the figure represents the standard 
deviation of the pixel intensities within each lane. Similar experiments were 
performed with the target DNA sequences from the other three pathogens. In 
Figure 3.11b, the concentration of the injected S. Zoo DNAs is 5×106 copies/mL. 
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In accord with the prediction, after the on-chip reactions, lanes 5 and 6 stand out 
clearly. Figure 3.11c and Figure 3.11d show the detection results for detection of 
target DNA sequences from viral pathogens EHV-1 and EHV4. Both experiments 
show clear evidence that the presence of target DNA can be specifically identified 
without inducing amplification in non-target lanes. The concentrations for the 
injected EHV-1 and EHV-4 DNAs were 5×106 copies/mL and 2×106 copies/mL 
respectively. Application of the thresholding criterion enables the system to 
differentiate positive from negative results in each lane.  
 
3.3.4 Detection of co-infection with two target DNA sequences present in the 
same sample 
Due to the increased risks brought by co-infections and the fact that the same 
clinical symptom can be caused by infections from several agents, a POC test 
which can simultaneously detect multiple pathogen-specific target sequences from 
a single specimen is highly desirable [27]. To further demonstrate the mobile 
genetic detection platform, we sought to introduce two target DNA sequences into 
the same test sample, and to detect positive response from only the corresponding 
lanes in the microfluidic chip. The sample prepared for this experiment contains 
4×104 copies/mL EHV-1 DNAs and 3.2×105 copies/mL EHV-4 DNAs, while the 
microfluidic chip is prepared as described previously. Results from this test are 
shown in Figure 3.12. As shown by the fluorescence image captured by the 
smartphone, the high-intensity lanes can be clearly identified as lane 1, the 
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positive control; lanes 7 and 8, which indicate the presence of EHV-1 DNA; as 
well as lanes 9 and 10, which indicate the existence of EHV-4 DNA. The lanes 
corresponding to the positive targets are significantly brighter than the negative 
control and the non-target lanes, and the thresholding method is able to 
differentiate between positive and negative results.  
 
3.4 Discussion 
As described in the Introduction, an important application for the technology 
platform presented in this work is for mobile diagnostics of pathogen-induced 
equine disease.  Respiratory disease is common in horses and difficult to diagnose 
using the current methods available to practicing veterinarians. Currently there is 
little to no monitoring of the health of horses even though they are the most 
valuable of livestock. Some respiratory conditions such as inflammatory airway 
disease (IAD) and interstitial lung disease are poorly understood [138] although 
animals are predisposed to these conditions by viral and bacterial infections [139], 
which occur worldwide [140]. Miniaturized and portable DNA analyses have 
emerged as promising tools for veterinary infectious diseases. State-of-the-art 
miniaturized systems that perform DNA amplification reactions can be classified 
as: small thermo-cyclers with integrated photodiodes [64, 141], microfluidic 
systems with customized optics for automated and multiplexed experiments [102, 
142, 143], and systems based on electrochemical principles that achieve 
miniaturization by removing optical elements [144, 145]. Small thermos cyclers 
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like ‘Palm PCR’ [141] let the user perform the reaction in a pocket-size device, 
but all the sample preparation is still performed by the user and there are no 
multiplexing capabilities. The microfluidic ‘FilmArray’ [142] system is highly 
automated and considerably reduces sample preparation and handling. However, 
the current technology is expensive, and a large footprint results in a bench-top 
system unsuitable for portable applications. Electrochemical-based systems like 
the one demonstrated by DNA Electronics [144]  monitor variables like pH 
change or secondary redox reactions to assess DNA amplification without optical 
elements. However, these alternatives require the compartmentalization of 
reactions since the monitoring variables are not specific to the target complicating 
assay multiplexing. 
In general, miniaturized DNA amplification systems seek to minimize 
footprint, automate processes, and reduce cost without sacrificing sensitivity and 
specificity of the assay [146]. Additionally, especially for infectious disease 
detection, it is desirable to have multiplexed assays that enable the screening of 
multiple agents in a single assay and it is important to create data networks to 
quickly analyze and share information to contain outbreaks. The devices 
referenced above fulfill some of these characteristics, but there is no system with 
all the desired features. The system that we describe in this work is tailored to 
fulfill the desirable characteristics for portable detection of infectious disease. For 
example, cost reduction is achieved by performing data acquisition, analysis, and 
broadcast using a smartphone instead of customized hardware. Also, the use of 
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preloaded microfluidic cartridges minimizes hands-on labor or required training. 
The goal of the detection system is also simplified to perform endpoint detection 
(i.e. not “real-time” PCR), and to provide only positive/negative output for each 
assay (rather than to estimate DNA copy number). All of the engineering and 
design parameters in our system can allow for the rapid detection of infectious 
agents with a mobile instrument that is capable of communicating information 
with a network of users. Importantly, the technology developed in this project is 
applicable to detection of any human infectious disease without modification to 
the sensor chip or the detection instrument through incorporation of human-
specific LAMP, and implementation of a sample preparation protocol compatible 
with blood, urine, stool, or other sample matrices.  
The most useful capability for a mobile veterinary laboratory and for 
human POC diagnosis is to simultaneously test for the presence of more than one 
pathogen with a single test protocol, which lowers cost, saves time/effort, and 
allows for a panel of pathogens, which may cause similar symptoms, to be 
identified. Multiplex LAMP or PCR assays using multiple primer sets in the same 
reaction can decrease the consumption of sample and reagent but is limited in 
detection sensitivity caused by uneven amplification efficiencies of the different 
primer sets [27]. The approach developed in this project splits the initial sample 
into multiple parallel flow channels for the multiplex LAMP-based detection. It 
takes less than 30 min to complete the on-chip amplification reactions, and the 
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existence of specific pathogens can be clearly identified through the brightness of 
the corresponding lanes on the smartphone-captured fluorescence images.  
The incorporation of a smartphone in the detection platform not only 
reduces the cost of the detection system but also makes it possible to establish a 
mobile network for the infectious disease epidemiology. The detection results can 
be collected by the smartphone app and transmitted through the mobile network 
for the reporting of the pathogens or further analysis at centralized laboratories. 
Due to the portability of the smartphone-based system, the detection can be 
quickly deployed and performed in a wide range of regions upon the outbreak of 
infectious disease, especially in resource-poor environments.  On the other hand, 
the same regions or countries, where the public health system has broken down, 
often face the highest risk of the emergence of new and once-controlled infectious 
diseases. A low-cost, portable and smartphone-integrated system provides a 
promising solution to address the challenges of infectious disease diagnostics in 
resource-limited settings. 
The smartphone-based detection system demonstrated here for 
identification of specific DNA sequences extracted from the pathogens of equine 
respiratory infectious diseases represents a significant step towards a practical 
solution to infectious disease diagnostics in resource-limited settings, and the 
establishment of a reporting network for infectious diseases. We envision that the 
detection system can be further optimized for field application and mobile 
infectious disease detection. Here, we intentionally choose to utilize an 
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inexpensive and commercially available DNA extraction kit to prepare the 
sample-to-detect since such kits are already portable and easily available. Because 
many inhibitors to the amplification-reaction are present in the sample from the 
respiratory tract, which can cause false-negative results, the extraction kit can 
help improve the accuracy of the detection [147]. The DNA extraction process is 
readily translatable to microfluidic formats to generate highly purified DNA for 
subsequent analysis, and it can be integrated into the same chip along with the 
DNA amplification and detection [148-150]. As for the further development of 
this research project, we envision a user in the field starting with unprocessed 
samples such as nasal swabs or throat swabs that are directly collected from the 
horses and then injecting the sample into the microfluidic chip for the sample-in 
and answer-out detection. The detection platform present here is clinically 
meaningful since the concentrations of the purified DNA detected through the 
system are all within the clinical range for the four types of pathogens [147, 151]. 
Importantly, the system is designed to provide a positive/negative determination 
of the presence of specific pathogens as a promising tool for early-stage disease 
detection. For the diagnosis of a suspect infection at early-stage, the main interest 
is to determine the presence or absence of virus or bacteria, while quantification is 
not strictly necessary. Such determination is valuable to the veterinary 
practitioners for the early reporting of and precaution against emerging infectious 
diseases. Based on the positive detection result of the smartphone-based 
instrument as well as other clinical signs, the detected sample can be sent to a 
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centralized laboratory or other disease administrator for further detailed 
diagnostics. 
 
3.5 Conclusion 
We demonstrate a smart, mobile, and low-cost service system for the detection of 
DNA sequences of viral and bacterial pathogens of equine respiratory infectious 
diseases. The system utilizes a microfluidic approach for performing LAMP-
based isothermal amplification of a multiplexed array of 1 to 10 pathogen-specific 
nucleic acid sequences, and uses a hand-held cradle that interfaces with the rear-
facing camera of a conventional smartphone to capture the fluorescence images. 
The captured images are analyzed by a smartphone app and shared to a cloud-
based center for rapid reporting of the detection results. Four LAMP assays have 
been developed for detection of the specific genes of four major pathogens that 
cause equine respiratory infectious diseases, including S. Equi, S. Zoo, and equine 
herpesvirus types 1 and 4. As compared with the assays performed on the bench-
top thermocycler apparatus in centralized laboratories, the detection sensitivity is 
not compromised using the microfluidic approach and the smartphone-based 
instrument. Importantly, the system is capable of detecting four types of target 
genomes at the same time to identify the presence or absence of the corresponding 
pathogens that can cause infection, and also to meet the challenges in diagnosing 
co-infections of multiple pathogen strains. By generating a positive or negative 
determination of the existence of specific pathogens, the mobile system can 
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inform treatment and quarantine responses for the detected infectious diseases that 
are currently not possible with tests performed at central laboratory facilities. We 
believe this approach provides a mobile, simple and inexpensive capability for 
clinicians to perform infectious disease diagnostics, and it represents a significant 
stride towards a practical solution to infectious disease diagnostics in resource-
limited settings.  
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3.6 Figures and Tables 
 
 
Figure 3.1: Ten-flow channel microfluidic chip for multiplexed LAMP 
detection. a) Schematic diagram of the fabrication process for the microfluidic 
chip. b) Photo of a fabricated chip taken with a US quarter. c)  Scanning electron 
microscope (SEM) of the cross-section of the microfluidic channels. d) Primer 
deposition plan for the on-chip reactions.  
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Figure 3. 2: Smartphone-based instrument. a) Schematic diagram to show the 
internal structure of the cradle that integrates optical and electrical components 
used for smartphone fluorescence microscopy. The microfluidic chip, integrated 
in its card, is inserted into the cradle that incorporates a PTC heater to maintain a 
constant ~ 65 °C temperature. b) Photo of the smartphone-based instrument taken 
with the smartphone and chip card. A QR code label is printed on the chip card to 
provide information about the on-chip detection.  
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Figure 3.3: The smartphone app developed for the recognition of the 
microfluidic channel regions of interest and the calculation the of the green 
pixel intensity of each channel.  
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Figure 3.4: Real-time measurement of the on-chip reactions when the sample 
contains only S. Zoo DNA. The images were captured at 1 min intervals using 
the fluorescence microscope. The images captured at a) 5 mins, b) 10 mins, c) 15 
mins, and d) 20 mins are shown here. Only the positive control and channels 
deposited with S. Zoo primers become bright.  
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Figure 3.5: Off-chip characterization of the four LAMP assays developed for 
the detection of equine respiratory infection pathogen DNA. The amplification 
curves and threshold time versus concentration relationship are plotted for a) S. 
Equi, b) S. Zoo, c) EHV-1, and d) EHV-4. 
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Figure 3.6: Off-chip verification of assay specificity. The real-time reaction 
curves of a) the S. Equi DNA, b) S. Zoo DNA, c) EHV-1 DNA and d) EHV-4 
DNA with all four primers and negative control. 
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Figure 3.7: On-chip characterization of the S. Zoo assay. The negative control 
a) and low DNA concentration test b) show no amplification within 60 min. c) 
The limit of detection for the on-chip reaction is 5×104 copies/mL. The 
amplification reactions begin within 15 min for the high concentration tests at d) 
5×105 copies/mL and e) 5×106 copies/mL. 
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Figure 3.8: On-chip characterization of the S. Equi assay detection limit. The 
limit of detection for the on-chip reaction is 5×104 copies/mL. 
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Figure 3.9: On-chip characterization of EHV-1 assay detection limit. The 
limit of detection for the on-chip reaction is 5×103 copies/mL. 
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Figure 3.10: On-chip characterization of EHV-4 assay detection limit. The 
limit of detection for the on-chip reaction is 5×103 copies/mL. 
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Figure 3.11: Experiments demonstrating one-at-a-time detection of target 
DNA sequences. Smartphone-captured images and intensities from each of the 
ten lanes on the fluorescence images are shown in a) for S. Equi detection, b) S. 
Zoo detection, c) EHV-1 detection and, d) EHV-4 detection. The LAMP reactions 
generate fluorescent output only in the positive control channel and the channels 
prepared with the specific primers. The existence of specific DNA sequence can 
be identified by the brightness of the lanes on the fluorescence images.  
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Figure 3.12: Demonstration of co-detection of multiple pathogen DNA 
sequences. The sample contains both the EHV-1 and EHV-4 DNA targets. Lane 1 
(the positive control), lanes 7 and 8 (the lanes for EHV-1), and lanes 9 and 10 (the 
lanes for EHV-4) become bright after the on-chip reactions.  
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Table 3.1. Sequences of primers used in the LAMP assays.  
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Table 3.2: Summary of the specificity of the four LAMP assays.  
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CHAPTER 4 
CONCLUSON  
 
We demonstrated mobile infectious disease detection platforms that can 
miniaturize the isothermal nucleic acid testing for the diagnosis of infectious 
diseases. A smartphone camera is used as the sensor in each platform for the 
measurement and analysis of the DNA amplification reactions performed on a 
microchip that is used to measure pathogen-specific nucleic acid sequences. The 
platform shown in Chapter 2 is designed for the quantitative detection of HIV in 
lyse whole blood, while the platform shown in Chapter 3 is able to identify the 
presence of multiple pathogens for equine respiratory infections.  
The wide availability of smartphones has provided a novel and effective 
way to access patients, diagnose their health status, and manage their health 
information, making mobile devices a good replacement for many bulky and 
expensive diagnostic instruments. Because of the rapid development of mobile 
technologies, “mHealth” is expected to play an important role in the future of 
personal care and medicine. The building of a smartphone-based system for 
biomedical detection can help with the fast diagnosis of infectious diseases. Such 
capability is of great significance considering the threats brought by the outbreak 
of unknown infectious diseases and the re-emergence of old infectious diseases. It 
can also help to build an efficient and practical disease reporting system for the 
control and prevention of infectious diseases. 
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